Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...
Study cohort began collecting data on newborns through adulthood, and may offer objective clues on asthma and COPD disease ...
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
This was the stock's fifth consecutive day of gains.
Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...
OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...
Regeneron (REGN) announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have ...
4hon MSN
We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...
Regeneron (NASDAQ:REGN) reported positive updated results from a Phase 1/2 study of its gene therapy DB-OTO in the treatment ...
Recent developments in the health sector include Pfizer appointing Patrizia Cavazzoni as Chief Medical Officer and Amgen ...
On February 18, 2025, in a closely watched decision, the United States Court of Appeals for the First Circuit in United States v.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results